Announcement on Change of Accounting Policies
Filed with SSE · · 2 pages · Chinese
Zhejiang East Asia Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang East Asia Pharmaceutical
- Announcement on Not Revising Downward Conversion Price of "East-Asia Convertible Bonds"
- Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for "East-Asia Convertible Bonds"
- Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
- Announcement on Wholly-owned subsidiary's Obtaining Registration Certificate for Drug Substance of Cefditoren Pivoxil from the Republic of Korea
- Announcement on Establishment of Wholly-owned Subsidiary Zhejiang Shanheng Pharmaceutical Co., Ltd. and Completion of Industrial and Commercial Registration
Later from Zhejiang East Asia Pharmaceutical
- Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
- Announcement on Obtaining Registration Certificate for Drug Substance of Trimebutine from the Republic of Korea
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Postponement of Investment Projects Financed by Funds Raised from Convertible Corporate Bonds
- Announcement on Change of Sponsor Representative for Continuous Supervision
Follow Zhejiang East Asia Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang East Asia Pharmaceutical